Schöffski P, et al. - Considering the observation that the inflammatory myofibroblastic tumour (IMFT), a rare mesenchymal neoplasm, is characterised by anaplastic lymphoma kinase (ALK) gene rearrangements, researchers investigated crizotinib, a tyrosine kinase inhibitor, for its activity and safety regarding targeting ALK in patients with advanced IMFT either with or without ALK alterations. In this trial, with 50% of participants with ALK-positive tumours achieving an objective response, crizotinib met the prespecified criteria for success. Results supported the rationale for inhibiting ALK in patients with IMFT. For patients with locally advanced or metastatic ALK-positive IMFT who do not qualify for curative surgery, crizotinib could be considered as the standard of care.